Vensica Medical Completes $500,000 Finance Round

Editor’s note: News of the Vensica raise appeared in Deal Street Asia, Globes, and Geektime (Hebrew).

Vensica Medical, a portfolio company of Trendlines Medical, announced the completion of a financing round of $500,000 from a private foreign investor. Vensica is developing a needle-free, painless procedure for the delivery of Botox® to treat overactive bladder. The company was founded in August 2014 and will use this investment for R&D and completion of device design.

Vensica Medical's Vensicare system

Vensica is developing VensiCare, an ultrasound catheter used to deliver Botox into the bladder wall.

Overactive bladder (OAB) — the most common type of bladder disorder — is the urgent need to urinate and involuntary loss of urine. The disorder has a profoundly negative impact on the quality of life of millions of people. It is estimated that there are 39 million people in the United States alone who suffer from OAB.

Medication is one treatment option, but it is ineffective in 50% of the cases and has significant side effects. In 2011, the FDA approved the use of Botox to treat OAB. While it has demonstrated effectiveness, the treatment is not without challenges: It is expensive, painful (20-30 injection sites), risky (urinary tract infections), and is most often performed under sedation.

Leveraging the known properties of ultrasound (opens pores and “pushes” drugs through them), Vensica is developing VensiCare, an ultrasound-catheter used to deliver Botox into the bladder wall. The procedure, performed in the doctor’s office or clinic — without anesthesia — is painless and eliminates the use of needles.

Vensica Medical CEO, Avner Geva, remarked, “Vensica is extremely pleased with the investment, which will allow us to complete development and begin the regulatory process. We are excited to be developing a product with the ability to improve the quality of life for so many people who suffer from OAB.“

“Vensica’s unique approach to improving a known treatment option for OAB and reducing patient discomfort is a true example of the type of exciting innovation that Trendlines Medical seeks, invests in, and supports. Vensica’s investment is a vote of confidence in their technology and direction,” added Eran Feldhay, CEO Trendlines Medical.

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+